Men1, the gene associated with multiple endocrine neoplasia type 1, menin polypeptides, and uses thereof
CA 2283476 C · Owner: Chandrasekharappa, Settara C. · Inventors: Spiegel, Allen M.; Guru, Siradanahalli C.; Zhuang, Zhengping
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to the discovery of a novel tumor suppressor gene which is associated with multiple endocrine neoplasia type 1. The gene has been designated MEN1 and the gene product is menin. The absence of this protein and associated mutations in the corresponding gene have been identified in individuals suffering from multiple endocrine neoplasia type 1. The identification of this marker for multiple endocrine neoplasia type 1 has diagnostic uses as well as for gene therapy.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 4, 1998 and granted August 14, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 4, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 4, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.